The American Journal of Managed Care

Phase 3 CheckMate-227 Trial Met Co-Primary Endpoint of PFS in NSCLC

This week, drug maker Bristol-Myers Squibb announced in a press release that the ongoing Phase 3 Checkmate-227 trial met its co-primary endpoint of progression-free survival with Opdivo plus Yervoy ...
pharmaphorum

Ipsen announces CheckMate 3-yr follow-up aRCC results

Ipsen has announced the three-year follow up results from its CheckMate -9ER study, showing that Cabometyx (cabozantinib) in combination with nivolumab shows durable survival benefits at over three ...
Nasdaq

Phase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma

In the first ever disclosure for the subcutaneous formulation of Opdivo, the CheckMate -67T Phase 3 trial demonstrates activity in advanced or metastatic clear cell renal cell carcinoma Company plans ...
The American Journal of Managed Care

CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus chemotherapy over six years. The combination therapy was particularly ...